Assessment of Metabolic and Pathological Response to Treatment With RCT and ImT Before Surgery in Locally Advanced Esophageal and Gastro-esophageal Junction Cancer: ARTemIS-Eso, a Three-level, Open-label, Phase I-II Study

Trial Profile

Assessment of Metabolic and Pathological Response to Treatment With RCT and ImT Before Surgery in Locally Advanced Esophageal and Gastro-esophageal Junction Cancer: ARTemIS-Eso, a Three-level, Open-label, Phase I-II Study

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Monalizumab (Primary) ; Fluorouracil; Oxaliplatin
  • Indications Adenocarcinoma; Gastrointestinal cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms ARTemIS-Eso
  • Most Recent Events

    • 26 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top